Lidocaine Hydrochloride Injection — FDA Drug Shortage
The FDA lists a drug shortage record for Lidocaine Hydrochloride Injection (injection) from Hospira, Inc., a Pfizer Company with status To Be Discontinued. The shortage was first posted on 11/07/2025.
Shortage Details
- Status
- To Be Discontinued
- Company
- Hospira, Inc., a Pfizer Company
- Package NDC
- 0409-4904-34
- Dosage Form
- Injection
- Presentation
- Lidocaine Hydrochloride, Injection, 1%, USP (For Cardiac Use Only) 50 mg/5 mL (10 mg/mL) LifeShield™ ABBOJECT® Glass Syringe (20 G x 1 1/2) (NDC 0409-4904-34)"
- Initial Posting
- 11/07/2025
- Revised Date